Long acting gastric residence system

1. A gastroretentive dosage form (GRDF) for extended retention in a human stomach, comprising:

a. a body comprising at least two arms, the body configured to transform between a collapsed configuration for ingestion, an expanded configuration for retention within the stomach and a disassembled configuration wherein after a predetermined time period has elapsed, the GRDF mechanically disassembles into at least two parts such that each of the disassembled parts of the GRDF is sized for exiting the stomach; and

b. an erodible insert comprising a therapeutic agent, a diagnostic agent, an electronical device, or a combination thereof;

wherein the disassembled configuration is induced by at least partial erosion of the erodible insert,

and

wherein at least a portion of at least one arm of said at least two arms forms a sleeve, tube or shell,

 wherein said sleeve, tube or shell of said at least one arm comprises a cavity and at least one opening,

wherein said erodible insert is housed in said cavity,

wherein said at least one opening is configured to expose said erodible

insert housed in said cavity to gastric fluid,

 wherein an uncoated surface area on said erodible insert overlaps with said at least one opening in said sleeve, tube or shell, thereby defining at least one overlapping area exposed to gastric fluid, and

wherein a sum area of said at least one overlapping area is less than 59.8 mm2, or less than 40.7 mm 2 , or less than 15.5 mm 2 .

2. The GRDF according to claim 1 , wherein a sum area of the at least one overlapping area is about 15.5 to about 59.8 mm 2 .

3. The GRDF according to claim 1 , wherein the body comprises at least three arms.

4. The GRDF according to claim 1 , wherein the body further comprises at least one hinge assembly configured to disengage from at least one arm upon at least partial erosion of the erodible insert.

5. The GRDF according to claim 1 , wherein the at least partial erosion of the erodible insert is at least 70% (w/w), at least 80% (w/w), at least 87% (w/w), at least 90% (w/w), at least 95% (w/w), at least 98% (w/w) or about 100% (w/w) erosion of the initial weight of the erodible insert.

6. The GRDF according to claim 1 , wherein the GRDF includes two or more overlapping areas.

7. The GRDF according to claim 1 , wherein the at least one overlapping area is equidistant from both ends of the erodible insert or ends of the arm.

8. The GRDF according to claim 1 , wherein the at least one overlapping area is located closer to one end of the erodible insert than to the other end of the erodible insert.

9. The GRDF according to claim 1 , wherein erosion of the erodible insert progresses bidirectionally from the overlapping area to both ends of the erodible insert.

10. The GRDF according to claim 1 , wherein the erodible insert comprises more than one therapeutic agent.